Alphyn Biologics Private Investor Breakfast - San Francisco

Dear Investors,

Opus8 is hosting a small, invitation-only investor breakfast during JPM Week featuring Alphyn Biologics, a late-clinical dermatology company entering Series B formation.

This closed-door session will provide direct access to the Alphyn management team and an opportunity to review recent clinical progress and upcoming milestones.

Alphyn Biologics is a late-clinical dermatology company developing patented, plant-derived topical therapeutics, led by a Phase 2a–completed asset in Atopic Dermatitis with additional pipeline programs including Molluscum Contagiosum Virus (MCV).

• Huge Market - Multi-target topical mechanism addressing multiple disease drivers

• Excellent Traction - Recently closed on $15 million Series A

• Strong safety and tolerability profile to date

• Patent protection in the U.S. and Europe extending to 2043

• Secured, regulatory-compliant raw material supply

Date: Sunday, January 11, 2026
Time: 9:30 AM PST
Location: Fogo de Chão, San Francisco

Attendance is limited and curated.

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

To request investor materials, contact:
Skylar Rallison — [email protected]

Thanks much and all the best,

Tien Wong

CEO

Opus8, Inc.

Know what’s Happening Next — before everyone else does.

Get App

Host or Publisher Opus8 Private Events